---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-043869"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:37:23.120090+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q4 2024 loss from ops $16.9M; cash $70.2M; BDC-4182 starts trial Q2 2025

## Summary
- Q4 2024 loss from operations $16.9M vs $19.8M in Q4 2023; full-year loss $73.0M vs $76.2M.
- Collaboration revenue Q4 $7.7M (up from $2.1M Q4 2023); full year $7.7M (down from $7.9M).
- Cash $70.2M expected to fund key milestones and operations through mid-2026.
- BDC-4182 on track to start Phase 1 trial in gastric cancer in Q2 2025.
- BDC-3042 Phase 1 fully enrolled at highest dose; no DLTs; data update expected Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-043869
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017025043869/0000950170-25-043869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017025043869/bolt-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-043869
- JSON: https://secwatch.observer/filing/0000950170-25-043869.json
- Plain text: https://secwatch.observer/filing/0000950170-25-043869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.